Want to join the conversation?
Biopharmaceutical company $GILD said the 48-week results from Study 1089, evaluating the safety and efficacy of switching virologically suppressed HIV-1 infected adult patients from F/TDF Truvada-based regimens to F/TAF-based regimens, showed improvements in renal and bone laboratory parameters in patients receiving F/TAF-based regimens.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)